Form D · Biotechnology

Elucid Bioimaging Inc.

Boston, MA · CIK 0001585931

Offering snapshot reported Oct 27, 2026 · SEC filing

Reported sold: $56.2M
Investors reported: 20
Minimum accepted: $0
First sale: Oct 10, 2025

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$36,495,008 → $56,235,000
Reported investors9 → 20

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 27, 2026	Amendment	$56,235,000	$19,739,992vs Oct 22, 2025	20	SEC filing
Oct 22, 2025	Initial	$36,495,008	No comparison	9	SEC filing
Nov 22, 2023	Initial	$78,950,836	No comparison	13	SEC filing
Sep 10, 2013	Initial	Yet to sell	No comparison	1	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-561638

Source: Form D, filed Oct 27, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Robert Braun	Director
Andrew J. Buckler	Executive
Shamiram Feinglass	Director
Kelly Huang	Director, Executive
Scott Huennekens	Director
Richard Kuntz	Director
Michael Lesh	Director
Evan Melrose	Director
Rajesh Panda	Director
Blake Richards	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

2 Park Plaza Suite 700
Boston, MA, 02116